BOLD BOUNDLESS BIO INC

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026.

The fireside chat session is scheduled for Thursday, February 12, in New York, NY, at 3:00 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, CA.

For more information, visit  and follow us on  and .

Contacts:

James Lee, Boundless Bio

Investors

Renee Leck



EN
05/02/2026

Underlying

BOLDBOUNDLESS BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BOUNDLESS BIO INC

 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biote...

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The fireside chat session is scheduled for Thursday, February 12, in New York, NY, at 3:0...

February 5, 2026 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Exte...

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028 SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the U....

January 20, 2026 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthca...

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. The fireside chat session is scheduled for Wednesday, December 3, in New York, NY, at 9:30 ...

November 24, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Reports Third Quarter 2025 Financial Results and Busines...

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights  Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to de...

November 5, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EOR...

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA. Details of t...

October 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch